• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

    8/6/24 4:05:00 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMVT alert in real time by email
    • Completed enrollment in batoclimab pivotal Myasthenia Gravis (MG) trial; top-line results and initiation of a potentially registrational program for IMVT-1402 on track for fiscal year end (March 31, 2025)
    • Progressed development of lead asset IMVT-1402 with 3 Investigational New Drug (IND) applications expected to be active by calendar year end (December 31, 2024)

    • Progressed Graves' disease (GD) program and on track to disclose additional results from the batoclimab study in GD as well as an overview of our development program for IMVT-1402 in GD in the fall of 2024

    • As of June 30, 2024, Immunovant's cash and cash equivalents totaled approximately $560 million

    NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal first quarter ended June 30, 2024.

    "We are encouraged by the progress we made this quarter on the execution of our plans for both batoclimab and IMVT-1402. Not only did we complete enrollment in our pivotal trial of batoclimab for MG, but we also continued to make great progress towards initiating pivotal trials with IMVT-1402 across a range of indications. This is very exciting given the uniquely positive features of both the anti-FcRn class and the uniquely positive potential benefits of IMVT-1402," said Pete Salzmann, M.D., chief executive officer of Immunovant.

    General Clinical Development Updates:

    Immunovant continues to focus on unlocking the full potential of IMVT-1402 for the benefit of people with underserved autoantibody-driven diseases and remains on course to initiate four to five potentially registrational programs by March 31, 2025. In pursuit of this goal, Immunovant expects to have at least three IND applications active by December 31, 2024 to support clinical development of IMVT-1402 in multiple indications. As previously announced, Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of 10 indications by March 31, 2026.

    Endocrinology Clinical Development Updates:

    Immunovant previously announced initial results from the ongoing Phase 2 open-label, proof-of-concept study assessing the safety and efficacy of batoclimab in GD. The study represents the first evaluation of an anti-FcRn in GD. In the fall of this calendar year, Immunovant plans to provide a GD program update consisting of new epidemiologic data characterizing the potentially addressable market, additional results from the batoclimab study, and an overview of the IMVT-1402 development program in GD.

    Top-line data from the current pivotal program evaluating batoclimab in thyroid eye disease (TED) continue to be expected in the first half of calendar year 2025. These data are expected to inform a decision regarding next steps for batoclimab in TED.

    Neurology Clinical Development Updates:

    Immunovant completed enrollment of the batoclimab pivotal trial in MG, with top-line results expected to be reported by March 31, 2025. Results from this trial are expected to inform a decision regarding next steps for batoclimab in MG. Immunovant also expects to initiate a potentially registrational program for IMVT-1402 in MG by March 31, 2025.

    Immunovant continues to enroll patients in the batoclimab chronic inflammatory demyelinating polyneuropathy (CIDP) trial. The data from this trial, as well as learnings from other CIDP trials, will be used to optimize the trial design for a potentially registrational program for IMVT-1402 in CIDP. Initial data from period 1 of the batoclimab CIDP trial and the trial design for IMVT-1402 in CIDP are both expected to be disclosed by March 31, 2025.

    Financial Highlights for Fiscal First Quarter Ended June 30, 2024:

    Cash Position: As of June 30, 2024, Immunovant's cash and cash equivalents totaled approximately $560 million.

    R&D Expenses: Research and development expenses were $75.5 million for the three months ended June 30, 2024, compared to $50.6 million for the three months ended June 30, 2023. The increase was primarily due to activities in preparation for potential future clinical trials of IMVT-1402, including contract manufacturing costs for drug substance, higher overall clinical trial costs related to our batoclimab pivotal clinical trials, and elevated personnel-related expenses. The increase was partially offset by lower overall costs related to our IMVT-1402 Phase 1 trial and nonclinical studies.

    IPR&D Expenses: There were no acquired in-process research and development expenses for the three months ended June 30, 2024. During the three months ended June 30, 2023, acquired in-process research and development expenses were $12.5 million related to the achievement of development and regulatory milestones for batoclimab under the terms of the HanAll in-license agreement.

    G&A Expenses: General and administrative expenses were $18.8 million for the three months ended June 30, 2024, compared to $15.4 million for the three months ended June 30, 2023. The increase was primarily due to higher personnel-related expenses, legal and other professional fees, information technology costs, and market research costs.

    Net Loss: Net loss was $87.2 million ($0.60 per common share) for the three months ended June 30, 2024, compared to $73.9 million ($0.57 per common share) for the three months ended June 30, 2023. Net loss for the three months ended June 30, 2024 and June 30, 2023 included $13.5 million and $10.7 million, respectively, related to non-cash stock-based compensation expense.

    Common Stock: As of June 30, 2024, there were 146,195,673 shares of common stock issued and outstanding.

    About Immunovant, Inc.

    Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. 

    Forward-Looking Statements

    This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," "may," "might," "will," "would," "should," "expect," "believe," "estimate," "design," "plan," "anticipate," "intend," and other similar expressions are intended to identify forward-looking statements. Such forward looking statements include statements regarding Immunovant's expectations regarding the timing, design, and results of clinical trials of IMVT-1402 and batoclimab, including the number and timing of (a) FDA clearance with respect to IND applications, and (b) potential registrational programs and clinical trials of IMVT-1402; Immunovant's plan to develop IMVT-1402 and batoclimab across a broad range of indications; and potential benefits of IMVT-1402's unique product attributes and potential best-in-class profile. All forward-looking statements are based on estimates and assumptions by Immunovant's management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others: Immunovant may not be able to protect or enforce its intellectual property rights; initial results or other preliminary analyses or results of early clinical trials may not be predictive of final trial results or of the results of later clinical trials; the timing and availability of data from clinical trials; the timing of discussions with regulatory agencies, as well as regulatory submissions and potential approvals; the continued development of Immunovant's product candidates, including the number and timing of the commencement of additional clinical trials; Immunovant's scientific approach, clinical trial design, indication selection, and general development progress; future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release; any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; Immunovant's product candidates may not be beneficial to patients, or even if approved by regulatory authorities, successfully commercialized; the potential impact of macroeconomic and geopolitical factors on Immunovant's business operations and supply chain, including its clinical development plans and timelines; Immunovant's business is heavily dependent on the successful development, regulatory approval, and commercialization of batoclimab and/or IMVT-1402; Immunovant is at various stages of clinical development for batoclimab and IMVT-1402; and Immunovant will require additional capital to fund its operations and advance batoclimab and IMVT-1402 through clinical development. These and other risks and uncertainties are more fully described in Immunovant's periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled "Risk Factors" in Immunovant's Form 10-Q to be filed with the SEC on August 6, 2024, and Immunovant's subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.



    IMMUNOVANT, INC.

    Consolidated Statements of Operations

    (Unaudited, in thousands, except share and per share data)
     
     Three Months Ended

    June 30,
      2024   2023 
    Operating expenses:   
    Research and development$75,473  $50,575 
    Acquired in-process research and development —   12,500 
    General and administrative 18,808   15,402 
    Total operating expenses 94,281   78,477 
    Interest income (7,180)  (4,065)
    Other income, net (28)  (464)
    Loss before provision (benefit) for income taxes (87,073)  (73,948)
    Provision (benefit) for income taxes 77   (11)
    Net loss$(87,150) $(73,937)
    Net loss per common share – basic and diluted$(0.60) $(0.57)
    Weighted-average common shares outstanding – basic and diluted 146,085,729   130,503,264 





    IMMUNOVANT, INC.

    Consolidated Balance Sheets

    (Unaudited, in thousands, except share and per share data)
     
     June 30, 2024 March 31, 2024
    Assets   
    Current assets:   
    Cash and cash equivalents$560,005  $635,365 
    Accounts receivable 2,417   5,337 
    Prepaid expenses and other current assets 26,625   25,068 
    Total current assets 589,047   665,770 
    Operating lease right-of-use assets 66   133 
    Property and equipment, net 565   462 
    Total assets$589,678  $666,365 
    Liabilities and Stockholders' Equity   
    Current liabilities:   
    Accounts payable$11,035  $7,155 
    Accrued expenses 33,914   41,315 
    Current portion of operating lease liabilities 69   138 
    Total current liabilities 45,018   48,608 
    Total liabilities 45,018   48,608 
    Commitments and contingencies   



    Stockholders' equity:   
    Series A preferred stock, par value $0.0001 per share, 10,000 shares authorized, issued and outstanding at June 30, 2024 and March 31, 2024 —   — 
    Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2024 and March 31, 2024 —   — 
    Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 146,195,673 shares issued and outstanding at June 30, 2024 and 500,000,000 shares authorized, 145,582,999 shares issued and outstanding at March 31, 2024 14   14 
    Additional paid-in capital 1,455,659   1,441,518 
    Accumulated other comprehensive income 1,820   1,908 
    Accumulated deficit (912,833)  (825,683)
    Total stockholders' equity 544,660   617,757 
    Total liabilities and stockholders' equity$589,678  $666,365 
        

    Contact:

    Renee Barnett, MBA

    Chief Financial Officer

    Immunovant, Inc.

    [email protected]



    Get the next $IMVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMVT

    DatePrice TargetRatingAnalyst
    3/3/2025$20.00Hold
    Jefferies
    1/3/2025Outperform → Peer Perform
    Wolfe Research
    10/10/2024$36.00Outperform
    Raymond James
    10/9/2024$47.00 → $53.00Outperform
    Oppenheimer
    3/28/2024$50.00Outperform
    Oppenheimer
    3/13/2024$50.00Buy
    Goldman
    2/20/2024$51.00Overweight
    JP Morgan
    2/15/2024$55.00Outperform
    Wolfe Research
    More analyst ratings

    $IMVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

      Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepointsINDs active for both MG and CIDP wi

      3/19/25 7:45:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The l

      3/18/25 4:32:00 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Immunovant Sciences with a new price target

      Jefferies initiated coverage of Immunovant Sciences with a rating of Hold and set a new price target of $20.00

      3/3/25 7:24:04 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Sciences downgraded by Wolfe Research

      Wolfe Research downgraded Immunovant Sciences from Outperform to Peer Perform

      1/3/25 7:34:55 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on Immunovant Sciences with a new price target

      Raymond James resumed coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $36.00

      10/10/24 8:38:30 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      1/15/25 4:36:38 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Roivant Sciences Ltd. was granted 4,473,684 shares and bought $58,000,008 worth of shares (1,526,316 units at $38.00), increasing direct ownership by 8% to 79,805,331 units (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      10/4/23 5:15:20 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Leadership Updates

    Live Leadership Updates

    See more
    • Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

      Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin

      9/23/24 8:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Mark Levine as Chief Legal Officer

      Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer. "We are extremely pleased to welcome Mark Levine as Immunovant's Chief Legal Officer," said Pete Salzmann, M.D., Chief Executive Officer. "Mark's broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization wil

      1/25/22 8:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Appoints Renee Barnett as Chief Financial Officer

      Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company," said Pete Salzmann, M.D., Chief Executive Officer. "Renee brings a deep understanding of drug developmen

      9/15/21 7:00:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunovant Inc.

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      11/12/24 10:32:13 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Immunovant Inc. (Amendment)

      SC 13G/A - Immunovant, Inc. (0001764013) (Subject)

      2/14/24 8:47:41 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immunovant Inc.

      SC 13G - Immunovant, Inc. (0001764013) (Subject)

      2/9/24 9:16:06 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    SEC Filings

    See more
    • SEC Form 144 filed by Immunovant Inc.

      144 - Immunovant, Inc. (0001764013) (Subject)

      5/21/25 4:24:45 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Immunovant Inc.

      144 - Immunovant, Inc. (0001764013) (Subject)

      5/19/25 4:40:29 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Immunovant Inc.

      S-8 - Immunovant, Inc. (0001764013) (Filer)

      4/30/25 4:06:19 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Girao Tiago was granted 208,388 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:09 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Susman Robert Graham was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:05 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bauer Jake was granted 25,016 shares (SEC Form 4)

      4 - Immunovant, Inc. (0001764013) (Issuer)

      5/5/25 7:30:07 PM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMVT
    Financials

    Live finance-specific insights

    See more
    • Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast

      3/18/25 4:32:00 PM ET
      $IMVT
      $ROIV
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

      Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector Additional results from batoclimab proof-of-concept study in GD, including 6-month treatment free remission data expected in summer 2025 Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Pro forma cash balance of approximately $825 million as of December 31, 2024, including approximately $450 mil

      2/6/25 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

      Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O

      11/7/24 6:30:00 AM ET
      $IMVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care